ArticleCancer research2009
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: a systematic review and patient-level survival data meta-analysis.Carcinogenesis · 2025Pooled it
- Impact of Chromosomal Instability and Aneuploidy in Cancer Development.Annual review of cancer biology · 2026Article
- Article
- Preclinical and Clinical Research Models of Prostate Cancer: A Brief Overview.Life (Basel, Switzerland) · 2022Review
- Calcium Signaling Alterations Caused by Epigenetic Mechanisms in Pancreatic Cancer: From Early Markers to Prognostic Impact.Cancers · 2020Article
- Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.Cancer cell · 2020Article
- Transcriptional regulators and regulatory pathways involved in prostate gland adaptation to a hypoandrogen environment.Genetics and molecular biology · 2020Article
- Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.International journal of molecular sciences · 2018Review
- Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer.Oncotarget · 2017Article
- Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer.Scientific reports · 2017Article
- LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.The Prostate · 2017Article
- Translational and clinical implications of the genetic landscape of prostate cancer.Nature reviews. Clinical oncology · 2016Review
- High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.The Journal of molecular diagnostics : JMD · 2016Article
- Mouse models of prostate cancer: picking the best model for the question.Cancer metastasis reviews · 2014Review
- Using high-density DNA methylation arrays to profile copy number alterations.Genome biology · 2014Article
- A transgenic mouse model for early prostate metastasis to lymph nodes.Cancer research · 2014Article
- Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer.Current gerontology and geriatrics research · 2014Review
- Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.American journal of clinical and experimental urology · 2014Review
- Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Review
- PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.Molecular cancer research : MCR · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
Androgen deprivation is the mainstay of therapy for progressive prostate cancer. Despite initial and dramatic tumor inhibition, most men eventually fail therapy and die of metastatic castration-resistant (CR) disease. Here, we characterize the profound degree of genomic alteration found in CR tumors using array comparative genomic hybridization (array CGH), gene expression arrays, and fluorescence in situ hybridization (FISH). Bycluster analysis, we show that the similarity of the genomic profiles from primary and metastatic tumors is driven by the patient. Using data adjusted for this similarity, we identify numerous high-frequency alterations in the CR tumors, such as 8p loss and chromosome 7 and 8q gain. By integrating array CGH and expression array data, we reveal genes whose correlated values suggest they are relevant to prostate cancer biology. We find alterations that are significantly associated with the metastases of specific organ sites, and others with CR tumors versus the tumors of patients with localized prostate cancer not treated with androgen deprivation. Within the high-frequency sites of loss in CR metastases, we find an overrepresentation of genes involved in cellular lipid metabolism, including PTEN. Finally, using FISH, we verify the presence of a gene fusion between TMPRSS2 and ERG suggested by chromosome 21 deletions detected by array CGH. We find the fusion in 54% of our CR tumors, and 81% of the fusion-positive tumors contain cells with multiple copies of the fusion. Our investigation lays the foundation for a better understanding of and possible therapeutic targets for CR disease, the poorly responsive and final stage of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.